13 clinical trials found.
-
AN OPEN-LABEL RANDOMIZED MULTICENTER PHASE Ib/II TRIAL EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
The purpose of this study is to test the safety of mosunetuzumab at different dose levels when given in combination with polatuzumab vedotin and to ...Phase
TRIAL ROLE: Sub Investigator
-
CDA Diefenbach Medpace Protocol ID ME-522-001 titled: A Phase 1 Open-label Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies
If you have been diagnosed with a B cell type cancer that has relapsed (come back) or is refractory (did not respond to previous treatment ...Phase
TRIAL ROLE: Sub Investigator
-
AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
If you have been diagnosed with non-Hodgkin s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that relapsed after previous treatment(s), did not respond to ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combination of Ipilimumab Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
If you have been newly diagnosed with relapsed/refractory Hodgkin lymphoma and are exploring treatment options, you may qualify for a clinical trial studying effect ...
Phase
TRIAL ROLE: Sub Investigator
-
A Three-Arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL) of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell Non-Hodgkin s Lymphoma (NHL) and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
The purpose of this study is to look at how your body tolerates ME-401, how effective ME-401 may be, and how ME-401 is taken up ...Phase
TRIAL ROLE: Sub Investigator
-
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine Rituximab High Dose Cytarabine and Acalabrutinib (BR/CR-A) and 3.) Bendamustine Rituximab and Acalabrutinib (BR-A) in Patients = 70 years old with Untreated Mantle Cell Lymphoma
The purpose of the study is to determine the efficacy and tolerability of bendamustine (B), rituximab (R) and high dose cytarabine (C) [(BR/CR] versus ...Phase
TRIAL ROLE: Sub Investigator
-
A Multi-center Open-label Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL
The purpose of the study is to optimize the dosage of calaspargase pegol in newly-diagnosed Philadelphia-negative acute lymphoblastic leukemia (ALL) patients based on age. We ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase IIa Open-label Clinical Trial to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
The first purpose of this study is to learn if combining the study drug BP1001 with the standard-of-care drugs Venetoclax and decitabine in first line ...Phase
TRIAL ROLE: Sub Investigator
-
A PHASE Ib STUDY EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF VENETOCLAX IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB (R) AND CYCLOPHOSPHAMIDE DOXORUBICIN PREDNISONE (CHP) IN PATIENTS WITH UNTREATED BCL-2 IMMUNOHISTOCHEMISTRY (IHC) POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
The purpose of this study is to test two different dosing schedules of an experimental drug called venetoclax. Venetoclax works by blocking a protein in ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
The purpose of the study is to determine the safety and tolerability of intravenous (IV) administered CLN-049. CLN-049 is a novel BITE therapy that target ...Phase
TRIAL ROLE: Sub Investigator
